Department of Pathology, Dupuytren University Hospital, Limoges, France.
Mod Pathol. 2010 Apr;23(4):619-28. doi: 10.1038/modpathol.2009.185. Epub 2010 Jan 15.
In glial tumors, the loss of heterozygosity of the 1p and 19q chromosomal arms is thought to be a marker of good prognosis in oligodendroglial tumors. However, 1p and 19q loss of heterozygosity may be telomeric, interstitial, centromeric or affect the whole arm of the chromosome and the associations between these different patterns and tumor type, other molecular markers and patient prognosis remain unclear. We analyzed microsatellite markers in a region spanning the chromosome from the telomere to the centromere, to characterize the pattern of 1p and 19q loss of heterozygosity in 39 infiltrative gliomas, including astrocytomas, glioblastomas, oligoastrocytomas and oligodendrogliomas. We then studied the association between loss of heterozygosity and the expression of p53 protein and Olig2, as analyzed using immunohistochemistry, and epidermal growth factor receptor (EGFR) gene amplification, as investigated using fluorescence in situ hybridization (FISH). Finally, we assessed the influence of molecular markers on the overall survival of patients. We identified five different 1p19q loss of heterozygosity patterns among the tumors studied and found that loss of heterozygosity over the whole 1p arm was associated with loss of heterozygosity over the whole 19q arm in 90% of cases. 1p19q whole loss was present in all the classical oligodendrogliomas, whereas other 1p19q loss patterns predominated in oligoastrocytomas. 1p19q whole loss was also significantly associated with Olig2 overexpression, but was never observed in tumors overexpressing p53 protein. We also found that, among patients with contrast-enhancing tumors, those with 1p19q whole loss tended to survive for longer. In combination with classical histological and immunohistochemical data, 1p19q status determination provides pertinent information useful for (1) discriminating between histological types of gliomas and (2) identifying a subgroup of tumors that are associated with a better prognosis.
在神经胶质肿瘤中,1p 和 19q 染色体臂的杂合性缺失被认为是少突胶质细胞瘤预后良好的标志物。然而,1p 和 19q 杂合性缺失可能是端粒、间质、着丝粒或影响整条染色体臂,这些不同模式与肿瘤类型、其他分子标志物和患者预后之间的关系尚不清楚。我们分析了跨越从端粒到着丝粒的染色体区域的微卫星标记,以描述 39 例浸润性神经胶质瘤(包括星形细胞瘤、胶质母细胞瘤、少突星形细胞瘤和少突胶质细胞瘤)中 1p 和 19q 杂合性缺失的模式。然后,我们研究了杂合性缺失与免疫组织化学分析的 p53 蛋白和 Olig2 表达之间的关系,以及荧光原位杂交(FISH)检测的表皮生长因子受体(EGFR)基因扩增之间的关系。最后,我们评估了分子标志物对患者总生存期的影响。我们在研究的肿瘤中确定了五种不同的 1p19q 杂合性缺失模式,发现整个 1p 臂的杂合性缺失与整个 19q 臂的杂合性缺失在 90%的病例中相关。所有经典的少突胶质细胞瘤都存在 1p19q 全缺失,而其他 1p19q 缺失模式则主要存在于少突星形细胞瘤中。1p19q 全缺失与 Olig2 过表达显著相关,但从未在过表达 p53 蛋白的肿瘤中观察到。我们还发现,在增强对比的肿瘤患者中,1p19q 全缺失的患者生存时间更长。结合经典的组织学和免疫组织化学数据,1p19q 状态的确定提供了有用的信息,有助于(1)区分神经胶质瘤的组织学类型,(2)识别与预后较好相关的肿瘤亚组。